Results 241 to 250 of about 361,742 (335)

Indications and Limitations of vNOTES for the Surgical Staging of Early-Stage Ovarian Cancer: A Narrative Literature Review. [PDF]

J Clin Med
Lygizos V, Vlachos DE, Haidopoulos D, Karagouni A, Varthaliti A, Fanaki M, Thomakos N, Damaskos C, Garmpis N, Tsourouflis G, Kykalos S, Athanasiou S, Dimitroulis D.   +12 more
europepmc   +1 more source

Identification of genetically predicted protein biomarkers and drug targets for prostate cancer via Mendelian randomization

VIEW, EarlyView.
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai, Tianming Peng, Zhiyue Xie, Chuqian Zhen, Chen Yao, Nan Peng, Qianyi Li, Yuzhong Yu, Jiming Bao, Xian‐Lu Song, Mingkun Chen, Shan‐Chao Zhao   +11 more
wiley   +1 more source

LAPTM5 drives omental metastasis in high-grade serous ovarian cancer via TGF-β/Smad-mediated epithelial plasticity. [PDF]

J Transl Med
Gao Y, Li J, Han X, Li Z, Cheng J, Hou L, Jiang M, Yin C, Yue W.   +8 more
europepmc   +1 more source

Mass spectrometry‐based mitochondrial proteomics for cancer biomarker discovery

VIEW, EarlyView.
Figure.1 Schematic diagram of MS‐based mitochondrial proteomics for cancer biomarker discovery. The workflow highlights the integration of advanced technological platforms in mitochondrial proteomics and their application in cancer biomarker discovery.
Zheng Cao, ZiKun Song, Weijie Zhou, Xiaohui Liu, Yanling Liu, Peng R. Chen, Kun Qian   +6 more
wiley   +1 more source

Harnessing m⁶A-regulated cholesterol biosynthesis helps impede tumor burden and stemness in high-garde serous ovarian carcinoma mesenchymal phenotype. [PDF]

Mol Med
Narayanan A, Dhenge K, Bapat SA.
europepmc   +1 more source

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

SNX1 inhibits human ovarian cancer progression via regulation of the cell cycle, apoptosis and migration. [PDF]

Mol Cell Oncol
Li P, Yu X, Wen K, Wang L, Yu J, Chen P.
europepmc   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer. [PDF]

J Transl Med
Wang H, Wang L, Zhu X, He M, Zhong L, Lv Y, Li Q, Jiang Q, Zhang C, Liu X, Zou D.   +10 more
europepmc   +1 more source

BRD9 inhibition as potential treatment option for testicular germ cell tumors

Andrology, EarlyView.
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen, Christine Sanders, Florian Fronhoffs, Kai Funke, Glen Kristiansen, Hubert Schorle   +5 more
wiley   +1 more source